Market Overview:
The global tissue engineered skin substitutes market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of burn injuries, diabetic foot ulcers, and other skin diseases. In addition, the increasing demand for advanced wound care products is also contributing to the growth of this market. The global tissue engineered skin substitutes market is segmented on the basis of type, application, and region. On the basis of type, it is divided into acellular, cellular allogeneic, cellular autologous and others. Cellular allogeneic segment dominates this market owing to its advantages such as low immunogenicity and easy availability as compared to other types segments. By application, it is classified into burn injury treatment (majorly), diabetic foot ulcer treatment (second majorly), vascular ulcer treatment (third majorly) and others including pressure sore treatment & post-operative healing etc.). Burn injury segment dominates this market due with high incidence rate across geographies followed by diabetic foot ulcers Segment .Geographically ,the global tissue engineered skin substitutesmarketis analyzedinto five regions namely North America , Latin America , Europe Asia Pacificand Middle East&Africa .
Product Definition:
Tissue-engineered skin substitutes (TESS) are biological materials that are engineered to replace or supplement the function of skin. They can be used to treat a variety of medical conditions, including burns, chronic wounds, and ulcers. Tissue-engineered skin substitutes can be made from a variety of different materials, including human cells and tissues, animal cells and tissues, or synthetic materials.
Acellular:
Acellular dermis is a type of tissue that is obtained from the removed or isolated epidermis from an animal source such as a pig. Acellular dermis has several advantages over autologous human skin in terms of its biocompatibility, low immunogenicity and ease of handling. The main driver for this market is the growing demand for tissue engineered skin substitutes especially in burn cases where there are no satisfactory alternatives available to date.
Cellular Allogeneic:
Cellular allogeneic is a type of skin substitute used in the treatment of burn patients. It is made from cells taken from an individual's own body and grafted onto the damaged area. The process involves taking skin cells from one location (such as the stomach, fat, or another part of the body) and putting them into a bioreactor to encourage them to grow into new tissue that can replace damaged or diseased tissue.
Application Insights:
The other application segment includes traumatic and burn injuries. The others segment dominated the global tissue engineered skin substitutes market in 2017 owing to the increasing number of patients suffering from chronic wounds. In addition, this segment is expected to grow at a lucrative rate during the forecast period due to rising healthcare costs and growing awareness about better wound care.
The diabetic foot ulcer treatment was one of the major applications witnessed in 2017. This can be attributed to an increase in diabetes-related foot ulcers due largely non-availability of advanced medical care for such ulcers coupled with high cost associated with them which makes it inaccessible for most people especially those living below poverty line globally.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to increasing R&D investments by private as well as government entities, rising healthcare expenditure, and growing adoption of technologically advanced products. In addition, presence of key players such as 3M and Medtronic in this region is expected to have a positive impact on the industry growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to factors such as improving healthcare infrastructure & reimbursement policies that enable easy access for tissue engineered skin substitutes for treatment coupled with high unmet needs regarding burn injuries & ulcers in this region which are driving factors for regional market growth.
Growth Factors:
- Increasing incidence of skin diseases and disorders: The global incidence of skin diseases is increasing at a rapid pace. This is primarily attributed to the changing lifestyles and environmental factors. According to a study by the World Health Organization, over 1 billion people are affected by some form of skin disease. This number is expected to rise in the coming years owing to the increasing pollution levels and changing lifestyles. This will create significant demand for tissue engineered skin substitutes as they offer an effective treatment option for various skin diseases and disorders.
- Growing awareness about tissue engineered skins: There is growing awareness among people about the benefits of using tissue engineered skins as compared to traditional treatments methods such as surgery or radiation therapy. Tissue engineered skins are non-invasive, less painful, and have shorter healing times than traditional treatments methods. They are also more affordable than other treatment options available in the market today. All these factors are contributing significantly towards the growth of this market worldwide
Scope Of The Report
Report Attributes
Report Details
Report Title
Tissue Engineered Skin Substitutes Market Research Report
By Type
Acellular, Cellular Allogeneic, Cellular Autologous, Others
By Application
Burn Injury, Diabetic, Vascular Ulcer, Others
By Companies
Amarantus BioScience Holdings, Acelity L.P., Inc., BSN medical, Integra LifeSciences Corporation, Medtronic (Covidien), Molnlycke Health Care, Smith & Nephew plc, Organogenesis, Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Tissue Engineered Skin Substitutes Market Report Segments:
The global Tissue Engineered Skin Substitutes market is segmented on the basis of:
Types
Acellular, Cellular Allogeneic, Cellular Autologous, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Burn Injury, Diabetic, Vascular Ulcer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amarantus BioScience Holdings
- Acelity L.P., Inc.
- BSN medical
- Integra LifeSciences Corporation
- Medtronic (Covidien)
- Molnlycke Health Care
- Smith & Nephew plc
- Organogenesis, Inc
Highlights of The Tissue Engineered Skin Substitutes Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Acellular
- Cellular Allogeneic
- Cellular Autologous
- Others
- By Application:
- Burn Injury
- Diabetic
- Vascular Ulcer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tissue Engineered Skin Substitutes Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tissue Engineered Skin Substitutes are artificial skin substitutes that are made from a variety of materials, including synthetic fabrics and plastics. They can be used to replace damaged or lost skin tissue, and they may also be used to improve the appearance of scarring or other cosmetic issues.
Some of the major companies in the tissue engineered skin substitutes market are Amarantus BioScience Holdings, Acelity L.P., Inc., BSN medical, Integra LifeSciences Corporation, Medtronic (Covidien), Molnlycke Health Care, Smith & Nephew plc, Organogenesis, Inc.
The tissue engineered skin substitutes market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Tissue Engineered Skin Substitutes Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Tissue Engineered Skin Substitutes Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Tissue Engineered Skin Substitutes Market - Supply Chain
4.5. Global Tissue Engineered Skin Substitutes Market Forecast
4.5.1. Tissue Engineered Skin Substitutes Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Tissue Engineered Skin Substitutes Market Size (000 Units) and Y-o-Y Growth
4.5.3. Tissue Engineered Skin Substitutes Market Absolute $ Opportunity
5. Global Tissue Engineered Skin Substitutes Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Type
5.3.1. Acellular
5.3.2. Cellular Allogeneic
5.3.3. Cellular Autologous
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Tissue Engineered Skin Substitutes Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Application
6.3.1. Burn Injury
6.3.2. Diabetic
6.3.3. Vascular Ulcer
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Tissue Engineered Skin Substitutes Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Tissue Engineered Skin Substitutes Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Tissue Engineered Skin Substitutes Demand Share Forecast, 2019-2029
9. North America Tissue Engineered Skin Substitutes Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Application
9.4.1. Burn Injury
9.4.2. Diabetic
9.4.3. Vascular Ulcer
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Type
9.7.1. Acellular
9.7.2. Cellular Allogeneic
9.7.3. Cellular Autologous
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Tissue Engineered Skin Substitutes Demand Share Forecast, 2019-2029
10. Latin America Tissue Engineered Skin Substitutes Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Application
10.4.1. Burn Injury
10.4.2. Diabetic
10.4.3. Vascular Ulcer
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Type
10.7.1. Acellular
10.7.2. Cellular Allogeneic
10.7.3. Cellular Autologous
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Tissue Engineered Skin Substitutes Demand Share Forecast, 2019-2029
11. Europe Tissue Engineered Skin Substitutes Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Application
11.4.1. Burn Injury
11.4.2. Diabetic
11.4.3. Vascular Ulcer
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Type
11.7.1. Acellular
11.7.2. Cellular Allogeneic
1.7.3. Cellular Autologous
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Tissue Engineered Skin Substitutes Demand Share, 2019-2029
12. Asia Pacific Tissue Engineered Skin Substitutes Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Application
12.4.1. Burn Injury
12.4.2. Diabetic
12.4.3. Vascular Ulcer
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Type
12.7.1. Acellular
12.7.2. Cellular Allogeneic
12.7.3. Cellular Autologous
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Tissue Engineered Skin Substitutes Demand Share, 2019-2029
13. Middle East & Africa Tissue Engineered Skin Substitutes Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Application
13.4.1. Burn Injury
13.4.2. Diabetic
13.4.3. Vascular Ulcer
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Tissue Engineered Skin Substitutes Market Size and Volume Forecast by Type
13.7.1. Acellular
13.7.2. Cellular Allogeneic
13.7.3. Cellular Autologous
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Tissue Engineered Skin Substitutes Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Tissue Engineered Skin Substitutes Market: Market Share Analysis
14.2. Tissue Engineered Skin Substitutes Distributors and Customers
14.3. Tissue Engineered Skin Substitutes Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amarantus BioScience Holdings
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Acelity L.P., Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. BSN medical
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Integra LifeSciences Corporation
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Medtronic (Covidien)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Molnlycke Health Care
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Smith & Nephew plc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Organogenesis, Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
